Two points of interest:
1. The mean time for a 505 b pathway approval is approx 18 months. https://www.raps.org/regulatory-focus™/news-articles/2017/3/505(b)(2)-approval-pathway-not-necessarily-shorter-approval-times
2. Two external experts. Who are they? Obviously commercial in-confidence. It suggests that a company is in early stage negotiations to partner.
Ann: FDA meeting provides guidance for TPM/Oxymorphone patch, page-6
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $3.137K | 1.148M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 68 | 104358077 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 25645581 | 11 |
View Market Depth
| Last trade - 15.17pm 03/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |